285130.KS Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 09:30):

Stats
Dzisiejszy wolumen	12 743.00
Średni wolumen	33 101.00
Kapitalizacja rynkowa	1 089.79B
EPS	KRW0 ( 2024-02-13 )
Następna data zysków	( KRW0 ) 2024-05-12
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW62.64 (0.11%)

Wolumen Korelacja

Długi: -0.12 (neutral)

Krótki: 0.48 (neutral)

Signal:(43.967) Neutral

SK Chemicals Co.,Ltd Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

SK Chemicals Co.,Ltd Korelacja - Waluta/Towar

0.30
( neutral )

0.55
( weak )

-0.77
( moderate negative )

-0.47
( neutral )

0.43
( neutral )

SK Chemicals Co.,Ltd Finanse

Annual	2023
Przychody:	KRW1 748.78B
Zysk brutto:	KRW460.54B (26.33 %)
EPS:	KRW2 077.30

FY	2023
Przychody:	KRW1 748.78B
Zysk brutto:	KRW460.54B (26.33 %)
EPS:	KRW2 077.30

FY	2022
Przychody:	KRW1 829.19B
Zysk brutto:	KRW615.09B (33.63 %)
EPS:	KRW9 915.20

FY	2021
Przychody:	KRW2 089.63B
Zysk brutto:	KRW881.38B (42.18 %)
EPS:	KRW5 351.19

Financial Reports:

No articles found.

SK Chemicals Co.,Ltd

SK Chemicals Co., Ltd. provides chemicals and life sciences products and solutions in South Korea and internationally. The company develops copolysters, coating and adhesive materials, engineering plastics, prepergs, bio materials, and 3D printing materials, as well as specialty chemicals, pharmaceutical products, and vaccines. It has a collaborate agreement with Standigm, Inc. to develop an AI-driven drug candidate for non-alcoholic steatohepatitis. The company was founded in 1969 and is headquartered in Seongnam, South Korea.